Rituximab in chronic lymphocytic leukemia
E Montserrat - Seminars in oncology, 2003 - Elsevier
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia but is currently
incurable by conventional therapeutic interventions. Rituximab has proven efficacy and
tolerability in non-Hodgkin's lymphoma, achieving response rates of 73% and 48% in
previously untreated or relapsed/refractory indolent non-Hodgkin's lymphoma, respectively.
However, the standard dose and schedule (375 mg/m2 once-weekly for 4 weeks) may not
be optimal for patients with previously treated small lymphocytic lymphoma, the …
incurable by conventional therapeutic interventions. Rituximab has proven efficacy and
tolerability in non-Hodgkin's lymphoma, achieving response rates of 73% and 48% in
previously untreated or relapsed/refractory indolent non-Hodgkin's lymphoma, respectively.
However, the standard dose and schedule (375 mg/m2 once-weekly for 4 weeks) may not
be optimal for patients with previously treated small lymphocytic lymphoma, the …
